Alzheimer's consortium how is it treated ?

The development of the next generation of Alzheimer's disease treatments is among the most important health needs worldwide, but presents huge challenges. New results, candidate therapeutics, and methodological issues will be some of the major worldwide issues discussed at the 2019 CTAD Congress. Alzheimer's disease symptoms and dementia treatment will be dealt with at the CTAD 2019 Congress. The CTAD 2019 Congress will provide the participants with new reports on the biomarkers from the clinical trial teams. Safe drugs represent some of the future treatment trials in order to avoid Alzheimer's disease progression. The importance of non-pharmaceutical trials and that anti-amyloid treatment for AD was shown at the 2018 CTAD Congress. Tau Biomarkers was proved to be one of the therapeutics combination as shown in the phase 43 clinical trials results. Again in 2019 Clinical teams will present their population studies on subjects in the early stage of the disease symptoms or even at the asymptomatic stage. The CTAD 2019 Congress will highlight the latest on trying to get these trials off the ground. Overall, the aim of the conference is to overcome the hurdles and speed the development of effective treatments. The JPAD Journal of Prevention of Alzheimer's Disease will publish reviews, original research articles and short reports to improve our knowledge in the field of Alzheimer prevention including : neurosciences, biomarkers, imaging, epidemiology, public health, physical cognitive exercise, nutrition, risk and protective factors, drug development, trials design, and health economic outcomes.